A carregar...
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
OBJECTIVES: Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen. METHODS: A Markov-based mic...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550431/ https://ncbi.nlm.nih.gov/pubmed/31166995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0217778 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|